Biotech Startups

Cumulus Oncology is a drug development company specializing in oncology therapeutics, leveraging experienced leadership with track records in new drug applications and successful M&A transactions. The company builds a risk-adjusted portfolio in the life sciences and pharmaceutical sector.

4 investors

CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling. It targets psychiatric and neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, neurogenic orthostatic hypotension, PSP, and ALS.

4 investors

Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.

4 investors

Curocell is a Korean biotech company developing CAR-T cell therapies for cancers such as lymphoma and leukemia, as well as autoimmune conditions like lupus. Its lead therapy anbalcel (marketed as Limkato) received manufacturing/marketing approval, making it one of Korea's most advanced CAR-T-focused companies.

4 investors

Curve Bio builds Whole-Body Intelligence models from its Whole-Body Atlas, a molecular map of the body, to power blood tests that monitor organ health in chronic disease patients. The company works in molecular diagnostics and biotechnology, focused on more accurate patient monitoring.

4 investors

Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation. The company is investing $32 billion in U.S. operations through 2030 to expand its research infrastructure and create domestic jobs.

4 investors

Cypher is an AI-native ELN and LIMS platform for life-sciences R&D teams, letting scientists record experiments, track samples with lineage, run analyses and bioinformatics pipelines, and order outside lab work, with an AI agent that operates on their own data. It serves drug discovery, synthetic biology, analytical chemistry and other R&D groups, offering cloud deployment with data residency in the US, EU or China.

4 investors

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.

4 investors

CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.

4 investors

DAAN Biotherapeutics develops T-cell immunotherapies for cancer, including TCR-T cell therapies, TCR-mimic T-cell engagers, and conditionally activated T-cell engagers targeting tumor-specific antigens. The company is building an immuno-oncology pipeline aimed at improving precision and reducing toxicity for patients with cancer.

4 investors

Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia. Its lead drug targets a specific subunit of the GABA-A receptor to improve neuronal function and reverse cognitive impairment.

4 investors

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

4 investors

De Novo Food Labs produces nature-identical bovine lactoferrin (branded NanoFerrin) using precision fermentation instead of dairy extraction, offering customizable iron saturation, purity, and sequence identity per batch. It supplies formulators of products such as infant formula, gut-health blends, and iron supplements with lactoferrin at lower cost and higher, more consistent volumes than traditional dairy sourcing.

4 investors

DeepCure uses AI and machine learning to accelerate drug discovery and development for treating diseases. The company combines computational biology with experimental validation to identify and optimize therapeutic candidates.

4 investors

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally. The company conducts research and development, collaborates with scientists and biotech innovators, and has reached millions of patients through its innovative therapeutic approaches.

4 investors

Diffuse designs proteins using AI models trained on experimental data collected through proprietary assays and software, delivering validated AI-designed proteins to partners.

4 investors

Digma Medical develops the Endoscopic Gastrointestinal Ablation Device (EGAD), a minimally invasive therapy using a console and single-use catheter for contactless, imaging-guided ablation of esophageal mucosal tissue, initially targeting Barrett's Esophagus. The device is designed for use in standard GI endoscopy suites and serves gastroenterology clinicians treating pre-cancerous and other GI pathologies.

4 investors

DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes. It focuses on new treatment options for diabetic patients as an alternative to lifelong exogenous insulin.

4 investors

DiscureMD is developing a treatment focused on disc degeneration, a leading cause of back pain that affects most adults during their lifetime.

4 investors

dNovo develops cellular reprogramming technology that converts patient-derived cells (blood, skin, or fat) into other cell types, with an initial focus on generating new hair to treat hair loss. The company, with research origins at Stanford and Harvard, aims to eventually produce cells, tissues, and organs on demand.

4 investors

Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers. The company has expanded from soil amendments to seed coatings that deliver biology directly on seeds, with plans to scale planter box treatments.

4 investors

Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.

4 investors

Edifice Health offers the Inflammatory Age test, a biomarker composite scoring system that measures and monitors a person's inflammatory and immune health for early detection and prevention of chronic disease. The test, derived from Stanford University research using omics platforms and AI, is provided to clinics, physicians, and healthcare providers to help manage patients' chronic inflammation and longevity.

4 investors

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer. The company focuses on in vivo genome editing approaches and serves patients worldwide with transformative, precision genomic medicines.

4 investors